🇺🇸 FDA
Patent

US 10258624

Modulators of cystic fibrosis transmembrane conductance regulator

granted A61KA61K31/404A61K31/415

Quick answer

US patent 10258624 (Modulators of cystic fibrosis transmembrane conductance regulator) held by Vertex Pharmaceuticals Incorporated expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
47
CPC classes
A61K, A61K31/404, A61K31/415, A61K31/44, A61K31/4418